The global Loperamide market is expected to grow at a significant CAGR during the forecast period (2021-2027).  Loperamide is a drug that has an antiperistaltic effect and is used to treat diarrhoea. It reduces faecal volume discharged from ileostomies by slowing down the movement of the muscles in the small intestine, which supports in taking out more water from the faeces, which is the waste matter, and allows more nutrients to be absorbed. It controls and relieves chronic diarrhoea associated with inflammatory bowel diseases as well as acute nonspecific diarrhoea.

The global loperamide market is being driven by an increase in awareness of antidiarrheal drugs with fewer adverse effects for treating diarrhoea. The FDA authorised package size and packaging type limits for over-the-counter (OTC) brand-name tablet and capsule forms of loperamide, an FDA-approved drug product that supports treating symptoms of diarrhoea, including Travelers' diarrhoea, in September 2019. By limiting each carton to no more than 48 mg of loperamide and necessitating unit-dose blister packaging, the adjustments to Imodium A-D, Imodium Multi-Symptom Relief, and Be Health Loperamide HCl Capsules are designed to address the problem of loperamide abuse and misuse. 

The maximum daily dose of OTC loperamide for adults is 8 milligrammes per day, and the maximum daily dose for prescription loperamide is 16 milligrammes per day. While loperamide is safe at allowed levels, the FDA has received reports of serious cardiac issues and deaths linked to the drug. The majority of serious heart problems were documented in people who were purposefully misusing and abusing high doses of loperamide. In 2017, loperamide Drug Facts labels were updated to include a Heart Alert warning, informing customers that taking more than prescribed can result in serious heart issues or death. Evidence suggests that limiting package size and using unit-dose packaging can help prevent medication overdose and death.being

Furthermore, the rise in the prevalence of diarrhoea cases, as well as an increase in government measures to improve healthcare facilities, have aided the growth of this market. Furthermore, developing countries have a strong chance of boosting this market's growth owing to the population living in poverty is large and having to deal with these concerns as a result of poor eating habits.  However, adverse effects associated with this treatment, as well as people's continued reliance on traditional and home remedies, are limiting the market growth.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o ByType 

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd., among others. 

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Loperamide Market Report by Segment

By Type 

    • Capsule

    • Tablet

    • Solution

    • Granule

By Application 

    • Hospitals 

    • Clinics 

    • Pharmacies

Global Loperamide Market by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa